Press Releases – Stem Cell Medicine Ltd.

Oral administration of a novel small molecule blocks the bone morphogenic proteins non-canonical\signaling pathways ameliorates EAE through oligodendrogenesis remyelination and preservation of axonal integrity and reduces astrogenesis

Post author:Ayelet Saciuk
Post published:April 17, 2024
Post category:Press Releases

Anti-BMP - ECTRIMS-ACTRIMS 2023 - Poster

Effects of SM on Myelination, axonal density, oligodendrogenesis and astrogenesis in EAE and on BMP signalling pathways

Post author:Ayelet Saciuk
Post published:October 13, 2023
Post category:Press Releases

Anti-BMP - ECTRIMS-ACTRIMS 2023 - Poster

Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Inflammatory and Toxic Demyelinating Disorders

Post author:Ayelet Saciuk
Post published:October 15, 2021
Post category:Press Releases

Poster P710 - ECTRIMS 2021 anti-BMP - Final

Exosomes Derived from Human Mesenchymal Stem Cells Ameliorate Autistic-like Behaviors

Post author:Ayelet Saciuk
Post published:April 23, 2019
Post category:Press Releases

Stem Cell Medicine Announces Late-Breaking News Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting JERUSALEM Israel, April 23, 2019 -- Stem Cell Medicine Ltd. (SCM), a biotechnology…

Stem Cell Medicine (SCM) Receives Israeli Government Funding for Gene Therapy Facility

Post author:Ayelet Saciuk
Post published:March 26, 2019
Post category:Press Releases

Production Facility to be built in Jerusalem JERUSALEM Israel, March 26, 2019 -- Stem Cell Medicine Ltd. (SCM), a biotechnology company developing new therapies for neurological indications and rare…

Stem Cell Medicine Licenses Exosome Technology for Treating Autism from Ramot at Tel Aviv University

Post author:Aviva Zyskind
Post published:January 2, 2019
Post category:Press Releases

MSC-exo Technology Has Potential to Treat Autism Using Novel Intranasal AdministrationPreclinical Studies Have Demonstrated a Benefit on Core Autism SymptomsJERUSALEM Israel, January 2nd, 2019 -- Stem Cell Medicine Ltd. (SCM),…

Human Muscle Progenitor Cells Ectopically Expressing Neurotrophic Factors to Enhance Intrinsic Neuronal Regeneration

Post author:Aviva Zyskind
Post published:April 30, 2018
Post category:Press Releases

Stem Cell Medicine Ltd. (SCM), will present the results of a study titled “Human Muscle Progenitor Cells Ectopically Expressing Neurotrophic Factors Enhance Intrinsic Neuronal Regeneration in a Sciatic Nerve Injury Mouse Model".

Stem Cell Medicine Signs License and Research Agreement with Ramot and Yeda to Develop Stem Cell-Based Treatments for Neuronal Diseases

Post author:Aviva Zyskind
Post published:December 2, 2015
Post category:Press Releases

Jerusalem, Israel, December 2, 2015 -- Stem Cell Medicine Ltd. (SCM), Ramot at Tel Aviv University Ltd. (Ramot), and Yeda Research and Development Company Ltd. (YEDA), announced today that they have entered into a license and research funding agreement...